Article date: 1991/7/12
PubMed ID: 1680062
Journal name: European journal of pharmacology (ISSN: 0014-2999)
A detailed pharmacological characterization of the quisqualate (QA) receptor coupled to phospholipase C (Qp) was performed in striatal neurons. The experiments were carried out in the presence of the ionotropic antagonists MK-801 (1 microM) and 6-cyano-7-nitroquinoxaline-2,3-dione (30 microM), concentrations that block N-methyl-D-aspartate (NMDA) or alpha-amino-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in these cells. QA, ibotenate and trans-1-aminocyclopentyl-1,3-dicarboxylate (ACPD) evoked dose-dependent inositol phosphate formations with EC50 values of 0.3, 6.7 and 29 microM, respectively. QA and ibotenate had the same maximal effect (295.7 +/- 17.9% of basal, n = 6) whereas the efficacy of ACPD was somewhat lower (70.2 +/- 8.9% of the maximal quisqualate effect, n = 4). The QA-, ibotenate- and ACPD-induced maximal effects were not additive, and the inositol phosphate formations induced by high concentrations of L-aspartate (L-ASP), AMPA, kainate (KA) and domoate (DO) (100 microM or higher) were also not additive. The inositol phosphate responses induced by all these agonists were totally blocked by the phorbol ester phorbol 12,13-dibutyrate (PdBu), but not by atropine or prazosin suggesting that all these substances were able to stimulate the Qp excitatory amino acid receptor in striatal neurons. Of the excitatory amino acid receptor antagonists tested, only D,L-2-amino-3-phosphonopropionate (D,L-AP3) inhibited QA-induced InsP formation in a competitive manner (mean pKi = 4.45 +/- 0.43, n = 4). However, this drug was also a partial agonist of the Qp receptor since it stimulated the inositol phosphate formation. We found that D,L-AP3 also inhibited NMDA-induced calcium increase, in a competitive manner (mean pIC50 = 4.34 +/- 0.22, n = 8, and mean pKi = 3.7 +/- 0.11, n = 5). The Qp excitatory amino acid receptor in striatal neurons therefore closely resembles Qp receptors with high potency for agonists as described in striatal and retinal slices and synaptoneurosomes, and has several pharmacological differences compared to the Qp receptors which have low potency for agonists described in hippocampal and cortical slices, cerebellar granule cells, astrocytes and rat brain mRNA-injected oocytes.
Author List: Manzoni O J, Poulat F, Do E, Sahuquet A, Sassetti I, Bockaert J, Sladeczek F A
Publication Types: Journal Article; Research Support, Non-U.S. Gov't
Substances mentioned in the article: Aminobutyrates; Inositol Phosphates; Quinoxalines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; 2-amino-3-phosphonopropionic acid; Phosphoserine; 2-Aminoadipic Acid; Ibotenic Acid; Phorbol 12,13-Dibutyrate; Dizocilpine Maleate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Type C Phospholipases; 2-amino-4-phosphonobutyric acid; domoic acid; Alanine; Kainic Acid; Fura-2;
Mesh terms: 2-Aminoadipic Acid/pharmacology; 6-Cyano-7-nitroquinoxaline-2,3-dione; Alanine/analogs & derivatives; Aminobutyrates/pharmacology; Animals; Cells, Cultured; Corpus Striatum/cytology; Dizocilpine Maleate/pharmacology; Fura-2/chemistry; Ibotenic Acid/pharmacology; Inositol Phosphates/metabolism; Kainic Acid/analogs & derivatives; Mice; Neurons/drug effects; Phorbol 12,13-Dibutyrate/pharmacology; Phosphoserine/pharmacology; Quinoxalines/pharmacology; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate/drug effects; Receptors, Neurotransmitter/drug effects; Type C Phospholipases/metabolism;